Will Chemours disclose material findings from the audit committee internal review by year-end 2026?

Base rate for 24+ month audit committee internal reviews producing material findings disclosure in the subsequent 8 months: 15-25%. Chemours' civil/criminal language in risk factor is unusual and elevates slightly, but current management alignment (zero sales, net accumulation) signals management does not anticipate personal exposure. Duration selection bias pulls up, insider signal pulls down. The 8-month window (April to December 2026) is short — even if findings are probable over 36 months, specific 2026 disclosure has lower conditional probability. Settle at 0.20.

The bimodal nature of extended reviews (either quiet close or material findings) argues that if findings were imminent, more leading-indicator signals would be present: auditor change, CFO departure, SEC subpoena disclosure, or mini-disclosures of specific findings. None are present per the committee record. Insider alignment is a meaningful negative leading indicator — executives accumulating stock ahead of material adverse disclosure would be insider-trading exposure. The most likely 2026 resolution is quiet close (no YES trigger) or continued standing language. 0.17 captures base-rate minus absence-of-leading-indicators.

The Catastrophist-Optimist committee debate converged on MATERIAL (not BENIGN) blindspot, which tilts probability upward from the raw base rate. ADM 2024 and Supermicro 2024 precedents are directly on-point for industrials/chemicals with audit committee issues. However, the specific 8-month window is short; most disclosures happen around quarter ends (Q1 10-Q in May, Q2 10-Q in August, Q3 10-Q in November, Q4 preliminary in February 2027). Four disclosure windows in 2026 gives ~4 independent shots but correlated because disclosure typically comes once decided. Net 0.22.

Balanced view: audit committee review duration argues for elevated probability (duration selection bias), but absence of leading indicators (auditor change, CFO departure, SEC subpoena) argues against imminent disclosure. Insider alignment is a mild negative signal. Base rate 15-25%. Lands at 0.19 — near the low end reflecting absence of leading indicators.

Conservative read: if material findings were imminent, insiders would be constrained by MNPI rules from accumulating. Current pattern of zero sales and uniform accumulation is strong revealed-preference signal against near-term disclosure. Base rate 15-25% but insider signal pulls toward lower end. 0.15 reflects revealed-preference weight.

Moderate view: MATERIAL consensus blindspot classification suggests committee believes probability is above random-benign rate, but specific 8-month window probability is modest. PFAS disclosure precedents (DuPont knowledge claims, 3M concealment) are conditioning events. Settle at 0.18 reflecting mid-range of the committee's framing.

Base rate for material findings from 24-month review in next 8 months is about 15-20%. Slight elevation for PFAS-era precedents. Insider alignment negative signal. Net 0.18.

Low probability — insider accumulation + no auditor change + no SEC subpoena + no restatement + 8-month window make near-term disclosure unlikely. Conservative anchor at 0.16.

Audit committee internal review at 24 months has meaningful conditional probability of eventual findings but 8-month specific window is 15-20%. Settle at 0.19.